Thirteen patients with acute myelocytic leukemia (AML) and with clonal aberrations involving chromosome 3 were studied. Three patients had monosomy 3, four had trisomy 3, and six had structural aberrations of chromosome 3. In the majority of cases chromosome 3 aberrations were parts of complex karyotypes, but in two patients, the abnormalities appeared as single aberrations, one as an interstitial deletion del(3)(p13p21) and the other as monosomy 3. All breakpoints of chromosome 3 were found in the fragile site regions 3p14.2, 3q21 and 3q26-27. All patients with monosomy 3 or structural aberrations of chromosome 3 and one of the four patients with trisomy 3 had been exposed to mutagens, such as occupational exposures to organic solvents and/or petroleum products or treatments with irradiation or antineoplastic agents. The association among mutagen exposure, structural chromosome 3 aberrations and fragile sites in AML may indicate that targeting of the mutagens to these sites is of importance for the etiology of the disease. Leukemia (2000) 14, 112-118.
Introduction
Structural and numerical aberrations of chromosome 3 have been identified in hematological diseases 1 as well as in other human malignancies. 2, 3 In acute myelocytic leukemia (AML), reports at the Fourth International Workshop on Chromosomes in Leukaemia found that 3% of the patients with AML had chromosome 3 aberrations when analyzed with banding techniques. 1 Aberrations of chromosome 3 are found in certain regions, 3p14-21, 3q21 and 3q26, in leukemias as well as in other malignant diseases, suggesting that these aberrations are non-random events important for the development of the malignancy. [2] [3] [4] Previous studies indicated an association between structural aberrations in the regions 3q21 and 3q26 and dysmegakaryocytopoiesis in leukemias of different types such as AML, [5] [6] [7] chronic myelocytic leukemia (CML) 8, 9 and myelodysplastic syndrome (MDS). 10, 11 Pedersen-Bjergaard et al 12 have shown that chromosome 3 aberrations are frequently present in therapy-related, secondary AML (t-AML) after treatments with irradiation and/or antineoplastic agents. Both balanced translocations involving 3q26 and 11q23 or 21q22, and deletions of chromosome 3 were observed. Molecular studies have shown that the region 3q21 harbors 10 different breakpoints in leukemia. These are combined with reciprocal translocations with other chromosomes such as 1, 5, 11, 12 and 15. 13 Studies of exposures to organic solvents or petroleum products have indicated an association with the development of leukemia. [14] [15] [16] [17] [18] 
Materials and methods

Patients
Thirteen patients with AML and chromosome 3 aberrations were investigated; six males and seven females. The median age was 62 years (range 16-84) ( Table 1 ). The patients participated in prospective treatment studies within the Leukemia Group of Middle Sweden (LGMS). 19, 20 Almost all patients with leukemia in this region are admitted to LGMS hospitals and enter co-operative treatment protocols. The study was approved by ethical committee of the Huddinge University Hospital, Karolinska Institutet.
The patients in the range of 16-60 years of age were given courses of drug combinations in randomized studies as follows: (1) POCAL (prednisolone + vincristine + cytosine arabinoside + adriamycin + thioguanine) or (2) POCAL-DNA (POCAL with adriamycin bound to DNA) or (3) DR (daunorubicin) + CYT (cytosine arabinoside). 19, 20 The elderly patients (Ͼ60 years) were treated with (1) DR + CYT or with (2) CYT or with (3) HIDAC (high-dose cytosine arabinoside) ( Table 1) .
Cytogenetics
Bone marrow samples for chromosome analysis were taken at diagnosis before cytostatic drug treatments. Bone marrow cells were analyzed both by direct method 21 and by in vitro culture for 24 h without mitogen. Peripheral blood cells were incubated for 48-72 h both with and without phytohemagglutinin (PHA) (Burroughs, Wellcome, UK) in RPMI medium with 10% calf serum as nutrient medium for bone marrow. For peripheral blood the patients own sera were used. For 2 h before harvesting, the cells were exposed to colchicine to a final concentration of 0.005 g/ml (Sigma, St Louis, MO, USA) for bone marrow and 0.05 g/ml for blood. Hypotonic treatment with potassium chloride solution 0.075 M was done before cell fixation with a mixture of 1:3 glacial acetic acid and of 100% methyl alcohol. The conventional Q-banding technique ad modum Caspersson 22 was used for chromosome staining and the International System for Human Cytogenetic Nomenclature (1995) was used for chromosome classification. 23 
Morphology
All bone marrow and blood samples were analyzed by the same investigator (ÅÖ ), without knowledge of the results of the chromosome analyses. The diagnostic procedures were 24, 25 with the slight modification of Ö st et al. 26 Dysmegakaryocytopoiesis was defined as an abnormal disturbed thrombocytopoiesis and/or reduction in the number of megakaryocytes as well as the presence of cytological abnormal megakaryocytes, especially hypolobulated, small megakaryocytes in the bone marrow. The CD61 antibody was not used in the analysis.
Environmental exposure and previous exposures to antineoplastic agents
Patient records and interviews with patients or the next of kin were used as sources of information concerning occupational and environmental exposures and medication before the diagnosis of AML. Occupational exposure was defined as full-time daily exposure to organic solvents and/or organic solventcontaining paints, glues and/or petroleum products and/or ionizing irradiation during a defined period of time.
17,18
Results
Chromosome analysis Numerical aberrations:
Four patients had clonal chromosome aberrations of the bone marrow cells including trisomy 3 in combination with other numerical and/or structural aberrations ( Table 2 ). Two of them had additionally an extra chromosome 8, the third patient had r(X), t(7;15)(q36;q22), and the fourth had −Y, del(17)(q23). Three patients had monosomy 3, one as a single aberration, one in combination with varying multiple trisomies and monosomy 16 and one with del(5)(q13), add(12)(p13), −15, −15, −17.
Structural aberrations:
Two patients showed structural aberrations in the region 3p13-21 ( Table 2 ). One of them had a single aberration, an interstitial deletion, del(3)(p13p21). The other patient had del(3)(p14-21) in combination with del(2)(p21), del(5)(q21) and i(11)(q10).
All four patients with structural aberrations of 3q had break- 
Chromosome 3 breakpoints and constitutive fragile sites
Constitutive or common fragile sites (c-fra) on chromosome 3 are located at 3p14.2 (FRA 3B), 3q21, 3q25, 3q26.2 and 3q27. 4 Two of the patients had breakpoints in the region of 3p14.2. Four patients had breakpoints in the region 3q21, one in addition in the region 3q25-29. All were exposed to mutagens (Table 3, Figure 1 ).
Exposure to environmental factors and cancer treatments
All nine patients with monosomy 3 or structural aberrations of chromosome 3 were exposed either to organic solvents, petroleum products, ionizing radiation, or antineoplastic agents (Table 3) . Among the four patients with an extra chromosome 3, only one was exposed to organic solvents. Time of exposure varied from 10 to 40 years. Two patients were treated for cancer of the ovary prior to AML. One of them was also treated for breast cancer and her karyotype was complex 45,XX,del(3)(q21),del(5)(q15-21), −7, add(9)(q34),del(10)(q22), inv(17)(q11q25). The karyotype of the other patient was 45,XX,−3. Another patient was treated for thyreotoxicosis with radioactive iodine orally. Her karyotype was 46,XY,t(3;8) (q13-21;p21),t(3;21)(q13-21;q22),del(7)(q31) ( Tables 2 and  3 ). 
Morphology and dysmegakaryocytopoiesis
There was no clear correlation between the specific type of chromosome 3 aberrations and FAB classifications. Dysmegakaryocytopoiesis was present in four patients, one with monosomy 3 and three with breakpoints at 3q21, in one of them in combination with a breakpoint in the region 3q25-29.
Prognosis
AML with monosomy 3 and structural aberrations of chromosome 3 were associated with poor prognosis. Only two of nine patients entered remission, which lasted 90 days for one aged 47 years and 96 days for one aged 33. The patients with trisomy 3 had longer times of remission (324 days, 642 days (death because of carcinoma of the ovary post-leukemia) and 260 days). One patient died on admission day without being treated.
Discussion
All patients with structural abnormalities of chromosome 3 or monosomy 3 had been occupationally exposed to organic solvents and/or petroleum products, or had therapeutic irradiation, antineoplastic drugs or radioactive iodine (Table  3 ). An increased risk of acute leukemia has previously been shown for people with occupational exposure to organic solvents 14, 17, 27 and petroleum products, such as gasoline or diesel fuels and motor exhausts. 15, 16, 18, 28 Benzene, an aromatic solvent, a constituent of organic solvents and lead-free gasoline is considered to be an important leukemogenic agent. 14, 27, 29, 30 Benzene is metabolized by cytochrome 450 2E1 to phenol and hydrochinone, catechol and muconic acid. 31, 32 It has been suggested that quinones and related free radicals are the ultimate toxic metabolites of benzene exhibiting their effects on topoisomerase II and on DNA thus capable Leukemia of inducing structural abnormalities. 29, 31, 32 Other mitotic disturbances can also be induced, creating cells with numerical aberrations. 29, 33 In the human environment there are many other sources, apart from benzene, of phenols and quinones. These compounds are present in coffee, cigarette smoke, food constituents, pharmaceutical preparations, skin lotions, lip balms and in photographic developer and may have etiologic importance for the development of a fraction of the acute leukemias. 31, 32 The high frequency of mutagen exposures in our patients indicates chromosome 3 as a possible target for these compounds.
Fragility of certain regions in the genome are suggested as targets for mutagen attacks with the creation of chromosome breaks and translocations. [34] [35] [36] [37] For example, benzene was shown to be a potent inducer of chromatide breaks at the fragile sites 3p14.2, 3q21, 3q25, 3q26.2 and 3q27. 38 These fragile regions were suggested as targets of mutagens that could cause chromosome abnormalities and furthermore to induce leukemia and lymphoma. 39 Two of our patients who were exposed to organic solvents containing benzene had chromosome breakpoints in the region of the fragile site 3p14.2, a site especially prone to show aberrations after exposure to benzene according to in vitro studies by Yunis et al. 38 Shi et al 40 noted a relationship between 3p aberrations and treatment-related AML, finding that two out of 11 patients with 3p21 aberration had secondary acute leukemia. Johansson et al 41 found that 3p deletions were more common in treatmentrelated AML than in de novo AML. Other studies lend support for the view that targeting of the fragile site FRA3B at 3p14.2 may be of importance in other types of cancer such as in cancer of the lung del(3)(p14p23), 42, 43 in kidney cancer 3p14.2, [44] [45] [46] in breast cancer del(3)(p12p14), 2, 3, 47 and in cancer of the ovary 3p13-21. 48 It was suggested that cancerspecific deletions at the FRA3B region (3p14.2) derived from breaks in fragile sites within the FHIT gene recently located to this region. 49 Although FHIT has been implicated as a cancer suppressor gene, this has still not been proven. 50 Sequence analysis of 276 kb of the FRA3B/FHIT locus and 22 associated cancer cell deletion-endpoints shows that this locus is 'a frequent target of homologous recombination between long interspersed unclear element sequences resulting in FHIT gene internal deletions, probably as a result of carcinogen-induced damage of FRA3B fragile sites'. 49 This association was confirmed in lung cancer, 51 breast cancer, 52 gastric cancer, 53 pancreatic cancer 54 and myeloid leukemia. 55 Four of our patients had breakpoints in the fragile siteregion 3q21. They were exposed to iodine-131, radiation and antineoplastic agents, petroleum products and organic solvents, respectively (Table 3) . The exposure to radioactive iodine has previously been reported to be associated with the development of leukemia. 56 Alimena et al 57 published a case of acute leukemia secondary to treatment with alkylating agents and topoisomerase II inhibitors with the aberration dup(3)(q21q26). Thus, these results support the view that mutagen targeting on fragile sites also to the chromosome region 3q21 may explain the association between the mutagens, the observed aberrations in the 3q21 region and leukemia.
The specific syndrome of dysmegakaryocytopoiesis has previously been described in patients with a breakpoint at 3q21 or an inversion 3 (q21q26) in both AML, 7 CML, 8, 9 and MDS, 10, 11, 58 which is frequently associated with monosomy 7, abnormal thrombopoiesis and poor prognosis. 9, 58, 59 Cases with only one of these breakpoints may have milder features of the syndrome. Dysmegakaryocytopoiesis was found in four of our patients. Three of them had structural aberrations at 3q21 (one was combined with an abnormality at 3q25-29) and one had monosomy 3. In one patient (No. 143) with t(AML), del(3)(q21) was combined with −7 and other abnormalities (Tables 1 and 2 ). Thus, our results confirm earlier reports on the association of dysmegakaryocytopoiesis and structural changes at the regions 3q21 and 3q26. The thrombopoietin gene is located on chromosome 3q26.33-q27. 60 It is probably not activated in the 3q21q26 syndrome. 61, 62 One of our exposed patients had, in addition to an abnormality at 3q21, a breakpoint at 3q25-29. In this region 3q26, there are two genes: MDS 1 and EVI 1 (Figure 1) . They have been implicated in acute myeloid leukemia. 63, 64 The t(3;21)(q26;q22) is a recurring abnormality in therapy-related acute myeloid leukemia and myelodysplastic syndrome. 65 These findings also suggest that this region is of importance for mutagenic attacks.
All patients with chromosome 3 aberrations but one with monosomy 3 and one with del(3)(p13p21), had complex karyotypes with involvement of chromosomes known to be abnormal in secondary leukemias (s-AML) and present after radiation and cytostatic treatments. 12, 40, 57, 65, 66 Exposure to environmental mutagens as well as mutagenic treatments preceded the development of AML. Thus the finding of complex karyotypes of occupationally exposed patients provides further support for the view that exposure is important for the etiology of the disease. Fragile sites could be preferential sites of mutagen interaction with the chromosomes, but the malignant transformation as a result of this interaction is also dependent on other factors such as the presence of regulatory genes of the cell in these loci. 67 Thus, although our results indicate an importance of fragile site regions as targets for mutagens and therefore for the development of leukemia, some controversies still remain as to the role of fragile site in the development of cancer. [68] [69] [70] 
